Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
MINT vs XBI: how they differ
MINT and XBI hold 0% of their weight in the same names, and XBI returned more over the year.
PIMCO Enhanced Short Maturity Active Exchange-Traded Fund and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, MINT and XBI hold 0% of their money in the same securities at the same weight.
| Only in MINT | Only in XBI |
|---|---|
| United States Treasury 6.51% | Apogee Therapeutics Inc 1.49% |
| Fannie Mae 1.18% | Moderna Inc 1.41% |
| Freddie Mac 1.04% | Twist Bioscience Corp 1.41% |
| SUMISHO AIR LEASE CORP 0.91% | Oruka Therapeutics Inc 1.38% |
| HSBC HOLDINGS PLC 0.81% | Kymera Therapeutics Inc 1.36% |
| AERCAP IRELAND CAP/GLOBA 0.81% | Viking Therapeutics Inc 1.31% |
| Trillium Credit Card Trust II 0.75% | Praxis Precision Medicines Inc 1.29% |
| INTL BK RECON & DEVELOP 0.73% | Erasca Inc 1.27% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026.
| MINT PIMCO Enhanced Short Maturity Active Exchange-Traded Fund | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | PIMCO | State Street |
| What it is | Enhanced Short Maturity Active Exchange-Trad | SPDR S&P Biotech |
| Total return, 1 year | +4.4% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | −13.1 pts | +46.5 pts |
| Expense ratio | 0.36% | 0.35% |
| Already in the S&P 500 | 9.7% | 8.5% |
| Holdings | 977 | 150 |
MINT in plain words
MINT is an index equity fund tracking the Enhanced Short Maturity Active Exchange-Trad. Over the year to Sep 11, 2026 it returned +4.4% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.36% a year. By its holdings filed for Jun 30, 2026, 10% of the fund by weight is stocks the S&P 500 also holds, across 977 positions, with the top ten at 14.1%.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, MINT or XBI?
- In the year to Sep 12, 2026, with distributions reinvested, MINT returned +4.4% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, MINT or XBI?
- MINT charges 0.36% a year and XBI charges 0.35%, so XBI is cheaper. Fees come from each fund's prospectus.
- How much do MINT and XBI overlap with the S&P 500?
- By their latest filed holdings, 10% of MINT and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 0% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, MINT against XBI, data as of Sep 12, 2026. https://etfiq.com/compare/any/MINT-XBI Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources